文献速递细菌感染、耐药与抗菌药物

土耳其2015-17年抗生素耐药性调查(SOAR):基于CLSI、EUCAST(剂量特异性)和PK/PD折点的数据

Results from the Survey of Antibiotic Resistance (SOAR) 2015-17 in Turkey: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
PubMed 文献 · J Antimicrob Chemother · 2020-01-01

该研究测定了2015-17年土耳其社区获得性呼吸道感染(CA-RTI)中分离的179株肺炎链球菌和239株流感嗜血杆菌的MIC,并用CLSI、EUCAST(剂量特异性)和PK/PD折点评估敏感性。肺炎链球菌对青霉素敏感性低(CLSI口服或EUCAST低剂量折点仅27.9%敏感),但高剂量折点下84.4%敏感;流感嗜血杆菌敏感性普遍较高。

要点

  • 肺炎链球菌对青霉素敏感性低,CLSI口服或EUCAST低剂量折点仅27.9%敏感。
  • 采用EUCAST高剂量或CLSI静脉折点时,84.4%的肺炎链球菌对青霉素敏感。
  • 流感嗜血杆菌对多数抗生素敏感性高,但氨苄西林和复方磺胺甲噁唑敏感性较低。

核心结论

  • 肺炎链球菌抗生素敏感性总体较低,与土耳其不适当和高抗生素使用的证据一致。
  • 流感嗜血杆菌敏感性较高,这些数据对CA-RTI的经验性治疗重要。

研究设计与样本

  • 2015-17年从土耳其社区获得性呼吸道感染中收集179株肺炎链球菌和239株流感嗜血杆菌。
  • 采用CLSI肉汤微量稀释法测定MIC,并用CLSI、EUCAST(剂量特异性)和PK/PD折点评估敏感性。

主要发现

  • 按CLSI折点(除青霉素静脉外),最活跃的抗生素为氟喹诺酮类(98.9%敏感)、头孢曲松(83.2%)、阿莫西林(78.8%)和阿莫西林/克拉维酸(78.8%)。
  • 肺炎链球菌对阿莫西林和阿莫西林/克拉维酸的敏感性在EUCAST低剂量折点下为49.7%,高剂量折点下为57.0%-58.1%,PK/PD折点下为78.8%-87.7%。
  • 23株流感嗜血杆菌为β-内酰胺酶阳性,其中11株按EUCAST标准、5株按CLSI标准被鉴定为β-内酰胺酶阴性氨苄西林耐药。
  • 流感嗜血杆菌按CLSI折点敏感性普遍较高:除氨苄西林(87%)和复方磺胺甲噁唑(67.4%)外,所有抗生素≥92.9%敏感;按EUCAST折点相似,但口服头孢呋辛仅3.8%敏感。
  • PK/PD折点显示对大环内酯类(5.9%-10%)和头孢克洛(13%)敏感性低。

关键数值与推荐

  • 肺炎链球菌对青霉素:CLSI口服或EUCAST低剂量折点敏感率27.9%,EUCAST高剂量或CLSI静脉折点敏感率84.4%。
  • 肺炎链球菌对阿莫西林/克拉维酸:EUCAST低剂量折点敏感率49.7%,高剂量折点57.0%-58.1%,PK/PD折点78.8%-87.7%。
  • 流感嗜血杆菌对氨苄西林:CLSI和EUCAST折点敏感率均为87%;对复方磺胺甲噁唑:CLSI 67.4%,EUCAST 72%。
  • 流感嗜血杆菌对口服头孢呋辛:EUCAST折点敏感率3.8%。
  • 流感嗜血杆菌对大环内酯类PK/PD折点敏感率5.9%-10%,对头孢克洛13%。

临床怎么用

  • CA-RTI经验性治疗应参考当地耐药数据,肺炎链球菌对青霉素敏感性低需考虑剂量或替代药物。
  • 流感嗜血杆菌对氨苄西林和复方磺胺甲噁唑敏感性较低,经验用药需谨慎。
  • 应用EUCAST剂量特异性折点可量化增加剂量对敏感性的影响,指导剂量优化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine antibiotic susceptibility of Streptococcus pneumoniae and Haemophilus influenzae isolates from community-acquired respiratory tract infections (CA-RTIs) collected in 2015-17 from Turkey. METHODS: MICs were determined by CLSI broth microdilution and susceptibility was assessed using CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. RESULTS: A total of 179 S. pneumoniae and 239 H. influenzae isolates were collected. Few (27.9%) pneumococci were penicillin susceptible by CLSI oral or EUCAST low-dose breakpoints, but by EUCAST high-dose or CLSI IV breakpoints 84.4% were susceptible. The most active antibiotics (excluding penicillin IV) by CLSI breakpoints were fluoroquinolones (98.9% of isolates susceptible), ceftriaxone (83.2%), amoxicillin (78.8%) and amoxicillin/clavulanic acid (78.8%). Pneumococcal susceptibility to amoxicillin and amoxicillin/clavulanic acid was lower using EUCAST low-dose breakpoints (49.7%), although susceptibility increased when using EUCAST high-dose (57.0%-58.1%) and PK/PD (78.8%-87.7%) breakpoints. Twenty-three H. influenzae isolates were β-lactamase positive, with 11 characterized as β-lactamase negative and ampicillin resistant following EUCAST criteria and 5 by CLSI criteria. Generally antibiotic susceptibility was high using CLSI breakpoints: ≥92.9% for all antibiotics except ampicillin (87% by CLSI and EUCAST breakpoints) and trimethoprim/sulfamethoxazole (67.4% and 72% by CLSI and EUCAST breakpoints, respectively). Susceptibility using EUCAST breakpoints (where these are published) was similar, except for cefuroxime (oral) with 3.8% of isolates susceptible. PK/PD breakpoints indicated low susceptibility to macrolides (5.9%-10%) and cefaclor (13%). The application of different EUCAST breakpoints for low and higher doses for some of the antibiotics (amoxicillin, amoxicillin/clavulanic acid, ampicillin, penicillin, ceftriaxone, clarithromycin, erythromycin, levofloxacin and trimethoprim/sulfamethoxazole) allowed, for the first time in a SOAR study, the effect of raising the dosage on susceptibility to be quantified. CONCLUSIONS: Antibiotic susceptibility of S. pneumoniae was generally low, which is in keeping with evidence of inappropriate and high antibiotic use in Turkey. H. influenzae susceptibility was high. These data are important for empirical therapy of CA-RTIs.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Torumkuney D, Tunger A, Sancak B, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2015-17 in Turkey: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. J Antimicrob Chemother. 2020. PMID: 32337598. doi:10.1093/jac/dkaa086

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。